EUCTR2006-001956-11-NL
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC
Cabrellis Pharmaceuticals Corporation0 个研究点目标入组 85 人2007年8月29日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Small Cell Lung Cancer (extensive stage)
- 发起方
- Cabrellis Pharmaceuticals Corporation
- 入组人数
- 85
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Histologically/cytologically proven small cell lung cancer Extensive disease as defined by Davis et al
- •WHO performance status 0\-2
- •Measurable disease according to RECIST criteria (imaging within 28 days prior to entry)
- •Age \= 18 years
- •Normal baseline cardiac function
- •No prior systemic chemotherapy for small cell lung cancer
- •Adequate haematological function (WBC \>1\.5 x 10 9 /L, platelets \>100 x 10 9 /L, Hb\> 9 g/dL)
- •Creatinine clearance: \= 60ml/min (Cockroft and Gault)
- •Adequate hepatobiliary function (ALT/AST \<2\.5 x Upper Limit of Normal)
- •All the blood tests should be performed within 14 days of patient inclusion.
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-BECelgene International SAR97
进行中（未招募）
1 期
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCEUCTR2006-001956-11-GBCelgene International SAR97
进行中（未招募）
不适用
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC ES - NDPatient with small cell lung cancer.MedDRA version: 6.1Level: PTClassification code 10041068EUCTR2006-001956-11-ITCABRELLIS PHARMACEUTICALS CORPORATIO85
尚未招募
2 期
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).NL-OMON30640European Organisation for Research in Treatment of Cancer (EORTC)14
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35